Bangkok Dusit Medical Services Public Company Limited
THAMSE:BDMS-F Stock Report
Market Cap: ฿421.1b
Bangkok Dusit Medical Services Valuation
Is BDMS-F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BDMS-F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BDMS-F (THB26.5) is trading below our estimate of fair value (THB30.93)
Significantly Below Fair Value: BDMS-F is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BDMS-F?
Key metric: As BDMS-F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for BDMS-F. This is calculated by dividing BDMS-F's market cap by their current
earnings.
What is BDMS-F's PE Ratio?
PE Ratio
27x
Earnings
฿15.63b
Market Cap
฿421.14b
BDMS-F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: BDMS-F is expensive based on its Price-To-Earnings Ratio (27x) compared to the TH Healthcare industry average (22x).
Price to Earnings Ratio vs Fair Ratio
What is BDMS-F's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
BDMS-F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
27x
Fair PE Ratio
31.4x
Price-To-Earnings vs Fair Ratio: BDMS-F is good value based on its Price-To-Earnings Ratio (27x) compared to the estimated Fair Price-To-Earnings Ratio (31.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.